HC Wainwright Brokers Reduce Earnings Estimates for Innoviva

Innoviva, Inc. (NASDAQ:INVA) – Research analysts at HC Wainwright lowered their Q1 2026 earnings estimates for shares of Innoviva in a report released on Monday, March 2nd. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will post earnings per share of $0.42 for the quarter, down from their previous forecast of $0.45. HC Wainwright has a “Buy” rating and a $46.00 price objective on the stock. The consensus estimate for Innoviva’s current full-year earnings is $0.33 per share. HC Wainwright also issued estimates for Innoviva’s Q2 2026 earnings at $0.51 EPS, Q3 2026 earnings at $0.48 EPS, Q4 2026 earnings at $0.55 EPS, FY2026 earnings at $1.96 EPS, Q1 2027 earnings at $0.53 EPS, Q2 2027 earnings at $0.65 EPS, Q3 2027 earnings at $0.63 EPS and Q4 2027 earnings at $0.69 EPS.

A number of other research analysts have also recently commented on INVA. Zacks Research cut shares of Innoviva from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 6th. Cantor Fitzgerald raised their target price on shares of Innoviva from $29.00 to $31.00 and gave the company an “overweight” rating in a research report on Thursday, November 6th. BTIG Research reiterated a “buy” rating and set a $35.00 price target on shares of Innoviva in a report on Thursday, February 26th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Innoviva in a report on Monday, December 29th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $38.17.

Innoviva Price Performance

Shares of INVA stock opened at $22.73 on Wednesday. The business has a fifty day simple moving average of $21.04 and a 200 day simple moving average of $20.12. The company has a market cap of $1.70 billion, a P/E ratio of 7.45 and a beta of 0.42. The company has a quick ratio of 13.85, a current ratio of 14.64 and a debt-to-equity ratio of 0.22. Innoviva has a twelve month low of $16.52 and a twelve month high of $25.15.

Innoviva (NASDAQ:INVA) last announced its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $1.94 EPS for the quarter, beating the consensus estimate of $0.34 by $1.60. Innoviva had a net margin of 65.92% and a return on equity of 37.63%. The business had revenue of $114.61 million during the quarter, compared to the consensus estimate of $102.62 million.

Institutional Investors Weigh In On Innoviva

A number of institutional investors have recently modified their holdings of the company. Creative Planning boosted its position in Innoviva by 0.8% during the third quarter. Creative Planning now owns 61,365 shares of the biotechnology company’s stock worth $1,120,000 after purchasing an additional 461 shares during the period. Bailard Inc. lifted its stake in shares of Innoviva by 4.7% during the 4th quarter. Bailard Inc. now owns 10,933 shares of the biotechnology company’s stock valued at $219,000 after buying an additional 492 shares in the last quarter. Verition Fund Management LLC boosted its holdings in Innoviva by 0.3% in the 3rd quarter. Verition Fund Management LLC now owns 175,855 shares of the biotechnology company’s stock worth $3,209,000 after buying an additional 527 shares during the period. Bank of Montreal Can boosted its holdings in Innoviva by 3.8% in the 4th quarter. Bank of Montreal Can now owns 14,742 shares of the biotechnology company’s stock worth $295,000 after buying an additional 540 shares during the period. Finally, Vise Technologies Inc. grew its stake in Innoviva by 6.1% in the 3rd quarter. Vise Technologies Inc. now owns 12,581 shares of the biotechnology company’s stock valued at $230,000 after buying an additional 724 shares in the last quarter. 99.12% of the stock is owned by institutional investors.

Innoviva News Roundup

Here are the key news stories impacting Innoviva this week:

• Positive Sentiment: HC Wainwright reiterates a Buy rating and a $46 price target, and publishes higher EPS forecasts for 2027 (signals confidence in longer‑term upside). HC Wainwright INVA Coverage
• Neutral Sentiment: Theravance Biopharma’s Phase 3 failure and restructuring are market headlines; impact on INVA depends on any direct commercial/royalty exposure (not documented in these notes), so treat as watch‑list risk. Theravance Trial Failure (Benzinga)
• Neutral Sentiment: Additional coverage on Theravance restructuring provides context on the program shut‑down; investors should verify any direct financial ties between Innoviva and Theravance before assuming material impact. Theravance Restructuring (TipRanks)
• Negative Sentiment: HC Wainwright trimmed several near‑term estimates: Q1–Q3 2026 and Q4 2026 cuts and a reduced FY2026 EPS view (FY2026 lowered to $1.96 from $2.23) — these downgrades to near‑term earnings could pressure sentiment if results or guidance follow the lower trajectory. HC Wainwright INVA Coverage

About Innoviva

Innoviva, Inc, incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva’s portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma.

The company was established through a spin‐out transaction in 2014, separating the royalty assets from a research‐based biopharmaceutical enterprise to create a specialized investment vehicle.